

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company.

This announcement is not for release, publication or distribution, in whole or in part, in or into any jurisdiction where to do so would constitute a violation of the applicable laws or regulations of such jurisdiction.



BioDlink International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1875)

**CLARIFICATION ANNOUNCEMENT IN RELATION TO THE
ANNOUNCEMENT
PURSUANT TO RULE 3.8 OF THE TAKEOVERS CODE**

Reference is made to: (i) the joint announcement dated 14 January 2026 issued by the Offeror, Wuxi Biologics and the Company in relation to, among others, the Offers (the “**Announcement**”); (ii) the composite document jointly issued by the Company and the Offeror dated 12 February 2026 in connection with the Offers (the “**Composite Document**”); and (iii) the announcement dated 1 March 2026 issued by the Company pursuant to Rule 3.8 of Takeovers Code (the “**Rule 3.8 Announcement**”). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as defined in the Announcement and the Composite Document.

The Board would like to clarify that, immediately after the vesting of the 142,000 Share Options on 1 March 2026, there are 7,632,600 outstanding Share Options, comprising (i) 7,490,600 Vested Unexercised Options; and (ii) 142,000 Unvested Options.

Save for the above, all the information and contents stated in the Rule 3.8 Announcement remains unchanged. This clarification announcement is supplemental to and should be read in conjunction with the Rule 3.8 Announcement.

By order of the Board
BioDlink International Company Limited
Mr. Fu, Shan
Executive Director

Hong Kong, 3 March 2026

As at the date of this announcement, the executive director of the Company is Mr. Fu, Shan; the non-executive director of the Company is Dr. Liu, Weidong; and the independent non-executive directors of the Company are Ms. Sun, Hui, Mr. Zhang, Qing and Dr. Gu, Xuelin.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.

This announcement is published in English and in Chinese. In case of any inconsistency between the English version and the Chinese version, the English version prevails.